JPS63503308A - 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 - Google Patents

抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法

Info

Publication number
JPS63503308A
JPS63503308A JP50303187A JP50303187A JPS63503308A JP S63503308 A JPS63503308 A JP S63503308A JP 50303187 A JP50303187 A JP 50303187A JP 50303187 A JP50303187 A JP 50303187A JP S63503308 A JPS63503308 A JP S63503308A
Authority
JP
Japan
Prior art keywords
lps
tnf
tumor
group
natural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50303187A
Other languages
English (en)
Japanese (ja)
Inventor
ホフマン，マイケル・ケー．
チユン，ミユン
ハマーリング，アルリツチ
Original Assignee
スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ filed Critical スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ
Publication of JPS63503308A publication Critical patent/JPS63503308A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50303187A 1986-05-09 1987-05-07 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法 Pending JPS63503308A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86156686A 1986-05-09 1986-05-09
US861,566 1986-05-09

Publications (1)

Publication Number Publication Date
JPS63503308A true JPS63503308A (ja) 1988-12-02

Family

ID=25336155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50303187A Pending JPS63503308A (ja) 1986-05-09 1987-05-07 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法

Country Status (4)

Country Link
EP (1) EP0271521A4 (de)
JP (1) JPS63503308A (de)
AU (1) AU7397887A (de)
WO (1) WO1987006830A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502080A (ja) * 2001-11-27 2006-01-19 シェーリング　コーポレイション 腫瘍由来樹状細胞阻害因子アンタゴニストおよびＴｏｌｌ様レセプターアゴニストの併用を使用する、癌を処置するための方法
JP2006518350A (ja) * 2003-02-18 2006-08-10 クリニーク ラ プレリー リサーチ エスエー 胎児ヘモグロビン、細菌エンドトキシン、および任意でさらなる胎児肝成分を含む組成物

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
EP0287633B1 (de) * 1986-10-16 1993-07-07 The President And Fellows Of Harvard College Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
JP2004521867A (ja) 2000-10-27 2004-07-22 イミュノ−アールエックス， インコーポレイテッド 免疫抑制された患者のためのワクチン免疫療法
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
EP1881080A1 (de) * 2006-07-18 2008-01-23 Institut Gustave Roussy Funktionsstörung des Toll-ähnliches Rezeptors 4 und biologische Anwendungen davon
CA2706445C (en) 2007-11-28 2019-07-23 Irx Therapeutics, Inc. Production of apoptosis-resistant t-lymphocytes for use in cancer therapy
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
US9333238B2 (en) 2009-12-08 2016-05-10 Irx Therapeutics, Inc. Method of immunotherapy for treament of human papillomavirus infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH643138A5 (de) * 1983-08-29 1984-05-30 Mepha Ag Indomethacin enthaltende, gelartige salbe.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502080A (ja) * 2001-11-27 2006-01-19 シェーリング　コーポレイション 腫瘍由来樹状細胞阻害因子アンタゴニストおよびＴｏｌｌ様レセプターアゴニストの併用を使用する、癌を処置するための方法
JP2006518350A (ja) * 2003-02-18 2006-08-10 クリニーク ラ プレリー リサーチ エスエー 胎児ヘモグロビン、細菌エンドトキシン、および任意でさらなる胎児肝成分を含む組成物

Also Published As

Publication number Publication date
EP0271521A1 (de) 1988-06-22
WO1987006830A1 (en) 1987-11-19
EP0271521A4 (de) 1989-11-14
AU7397887A (en) 1987-12-01

Similar Documents

Publication Publication Date Title
US4980160A (en) Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
Costelli et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.
Schade et al. Endotoxin tolerance
JPS63503308A (ja) 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法
EA030513B1 (ru) Комбинированная фармацевтическая композиция и способ лечения и профилактики инфекционных заболеваний
JPH0586379B2 (de)
Futami et al. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
US5961969A (en) Stable circulating histamine levels
Hersh Immunosuppression by L-asparaginase and related enzymes: A review
Sredni et al. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.
EP0303687B1 (de) Zubereitungen zur verbesserung der adcc-therapien
US5096707A (en) Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
Chun et al. Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems
Tabata et al. In vivo effects of recombinant interferon alpha A/D incorporated in gelatin microspheres on murine tumor cell growth
EP0287633B1 (de) Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen
EP1347773B1 (de) Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
KIKUCHI et al. Effects of naloxone on human ovarian cancer cell growth in vitro and in vivo
Lane et al. The Antitumor Activity of 5-Bis-(2′-chloroethyl)-Aminouracil (Uracil Mustard)
US3326761A (en) 6-demethyl-6-deoxytetracycline, anti-tumor antibiotic
Wimer et al. Mitogen information summaries
JPS61502123A (ja) 抗腫瘍活性を有する薬剤学的生成物；抗腫瘍療法への薬剤学的生成物または薬剤学的組成物の使用
Schultz et al. Potentiation of nonspecific immunotherapy of experimental lung metastases by indomethacin
JPS5995220A (ja) 免疫療法剤
Umezawa The Leeuwenhoek Lecture, 1982-Studies of microbial products in rising to the challenge of curing cancer
Amiel et al. Effects of active specific and non-specific immunotherapy on E♂ G2 leukaemia according to the route of administration and combination of immunological stimulants